Scarica l'app Stockscreener
43.62
0.71%
-0.31
Pre-mercato:
43.58
-0.04
-0.09%
Tempus Ai Inc Borsa (TEM) Ultime notizie
Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
ARK Invest Increases AI and Genomic Holdings While Reducing Semi - GuruFocus
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here - Barchart.com
7 Healthcare AI Stocks Under $50 With Huge Upside Potential - 24/7 Wall St.
Cathie Wood’s weekly update: buys Cerebras, Tempus AI, sells AMD and TSM (ARKK:BATS) - Seeking Alpha
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Tempus AI stock jumps, ALERT trial results boost EHR automation buzz - MSN
Tempus AI stock gains following the ALERT trial result announcement - MSN
Cathie Wood buys $14.9 million of Tempus AI stock - MSN
Tempus AI Inc (TEM) Stock Price, Quote, News & History - Benzinga
Tempus AI (TEM) executive Fukushima Ryan makes bona fide stock gifts under lock-up - Stock Titan
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell? - TradingView
Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tempus AI shares gain after expanded partnership with Gilead - MSN
Alzheimer’s Blood-Based Biomarker Testing Integrated into Clinical Workflows - Clinical Lab Products
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - Quantisnow
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Here’s Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company - Insider Monkey
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Baillie Gifford Reduces Stake in Tempus AI Inc: A Strategic Port - GuruFocus
Tempus AI Announces $350M Convertible Senior Notes Offering to Repay Debt and Enhance Financial Flexibility - Minichart
Tempus AI Completes Convertible Notes Offering, Retires Secured Debt - TipRanks
Tempus AI Prices $460 Million 0% Convertible Notes Due 2032, Retires Senior Credit Facility - TradingView
AI In Medical Imaging Market Expected to Witness Rapid Expansion - openPR.com
TEM Stock Price, Quote & Chart | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
Tempus AI (NASDAQ: TEM) prices $460M 0% 2032 convertible notes and repays debt - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Piper Sandler Maintains Tempus AI(TEM.US) With Hold Rating, Maintains Target Price $58 - Moomoo
Ark Invest Again Sells AMD, This Time As Stock Hits 52-Week High While Snapping Up Tempus AI And Circle - Benzinga
Cathie Wood’s ARK sells AMD stock, buys Kratos and Tempus AI - Investing.com
Tempus AI prices upsized $400M offering - MSN
Artificial Intelligence Stocks Worth WatchingMay 11th - MarketBeat
How Lucent and Tempus Are Using AI to Spot Alzheimer’s Earlier - HIT Consultant
H.C. Wainwright cuts Tempus AI stock price target to $64 on wider losses By Investing.com - Investing.com Australia
H.C. Wainwright cuts Tempus AI stock price target to $64 on wider losses - Investing.com UK
H.C. Wainwright Maintains Tempus AI(TEM.US) With Buy Rating, Cuts Target Price to $64 - Moomoo
Digital tool that flags high-risk patients wins global health tech award - Stock Titan
Tempus AI, Inc. (TEM) Stock Analysis: Exploring The 38.92% Potential Upside For Investors - DirectorsTalk Interviews
Cathie Wood Dumps Another $3 Million In AMD Stock As Ark Invest Trims For Third Day Running, This Is the AI Stock She Is Buying Instead - Yahoo Finance
Tempus AI (TEM) Valuation Check As Q1 2026 Growth And New Pharma Collaborations Refocus Attention - simplywall.st
Tempus AI Raises US$400m As Alzheimer’s Collaboration Broadens Diagnostic Reach - Sahm
Lucent Diagnostics and Tempus AI partner to expand access to Alzheimer’s blood biomarker testing - SelectScience
Top Artificial Intelligence Stocks To ResearchMay 10th - MarketBeat
Is Tempus AI (TEM) The Best AI Healthcare Stock to Buy? - Insider Monkey
Tempus AI targets $1.59B-$1.6B revenue and about $65M adjusted EBITDA in 2026, backed by Merck collaboration - MSN
Tempus AI plans $350M convertible notes offering - MSN
BTIG Maintains Tempus AI (TEM) Buy Recommendation - MSN
Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance - Yahoo Finance
Tempus AI (TEM) reports Q1 loss, beats revenue estimates - MSN
1.06%
2.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):